Parallax Volatility Advisers’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-7,298
Closed -$70K 2918
2022
Q3
$70K Buy
+7,298
New +$73.9K ﹤0.01% 2556
2018
Q2
Sell
-8,514
Closed -$122K 2195
2018
Q1
$94K Sell
8,514
-16,508
-66% -$181K ﹤0.01% 1381
2017
Q4
$220K Buy
25,022
+24,001
+2,351% +$257K ﹤0.01% 2208
2017
Q3
$14K Buy
1,021
+290
+40% +$3.84K ﹤0.01% 1724
2017
Q2
$10K Buy
+731
New +$14.1K ﹤0.01% 1988

Other funds holding CHRS

Parallax Volatility Advisers's CHRS Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of Coherus Oncology (CHRS) in Q4 2022, closing a stake of 7,298 shares — an estimated $70K sold.

Parallax Volatility Advisers first reported a position in CHRS in Q2 2017 and held it in 5 quarters. The position peaked at $220K in Q4 2017. 161 funds tracked by Wall St. Rank hold CHRS as of Q4 2022.

  • Parallax Volatility Advisers reported no remaining Coherus Oncology position as of Q4 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 7,298 Coherus Oncology shares in Q4 2022, an estimated $70K.
  • Parallax Volatility Advisers first reported a position in Coherus Oncology in Q2 2017 and held it in 5 quarters.
  • Parallax Volatility Advisers's Coherus Oncology position peaked at $220K in Q4 2017.
  • 161 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.